Eli Lilly and Novo Nordisk Lead the Obesity Treatment Market
NVO Novo Nordisk ADR
$41.63 +2.41%
View chart & analysis → - 1Eli Lilly recorded a 39% year-over-year revenue growth rate in the third quarter.
- 2Eli Lilly achieved $24.4 billion in revenue in the third quarter.
- 3Novo Nordisk's net sales grew 6% year-over-year in the third quarter.
So what's the key point?
Eli Lilly's revenue increased significantly by 39% compared to last year. Both companies leading the obesity treatment market earned more money.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.